Paula Swain - Incyte Executive Resources
| INCY Stock | USD 75.45 0.65 0.87% |
Executive
Ms. Paula J. Swain is the Executive Vice President Human Resources of Incyte Corporationrationration. She has served as Executive Vice President, Human Resources since August 2002 and joined Incyte as Senior Vice President of Human Resources in January 2002. Ms. Swain served as Senior Vice President of Human Resources at BristolMyers Squibb Company from October 2001 to January 2002, after it acquired DuPont Pharmaceuticals Company. From July 1998 to October 2001, Ms. Swain was Senior Vice President of Human Resources at DuPont Pharmaceuticals. From October 1992 to July 1998, Ms. Swain held a variety of human resources positions of increasing responsibility at DuPont Pharmaceuticals since 2002.
| Age | 66 |
| Tenure | 22 years |
| Address | 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 |
| Phone | 302 498 6700 |
| Web | https://www.incyte.com |
Incyte Management Efficiency
Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ellen Rosenberg | Amicus Therapeutics | 61 | |
| Samuel Wadsworth | Ultragenyx | 76 | |
| Francesca Nolan | Sarepta Therapeutics | N/A | |
| Laura Hansen | Denali Therapeutics | N/A | |
| Ari Maizel | Axsome Therapeutics | N/A | |
| Holly Valdiviez | ACADIA Pharmaceuticals | N/A | |
| Erik MBA | Ultragenyx | 54 | |
| Dr BSc | Ionis Pharmaceuticals | 67 | |
| Jeffrey MBA | Harmony Biosciences Holdings | 52 | |
| Greg Guyer | Biomarin Pharmaceutical | 62 | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
| Jason Radford | BeiGene | 42 | |
| Aaron Olsen | Ultragenyx | N/A | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Amy Wireman | Biomarin Pharmaceutical | N/A | |
| Amanda PharmD | Axsome Therapeutics | 41 | |
| Hayley Soffer | Ionis Pharmaceuticals | N/A | |
| Parag PharmD | ACADIA Pharmaceuticals | N/A | |
| Holly Hobson | United Therapeutics | N/A | |
| MBA MD | Arrowhead Pharmaceuticals | 46 | |
| Timothy Maines | Alnylam Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.008 | ||||
| Return On Asset | -0.0012 |
Incyte Leadership Team
Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Tray, Chief Finance | ||
| Pamela Murphy, Vice Communications | ||
| Sheila JD, General VP | ||
| Paula Swain, Executive Resources | ||
| Christine Chiou, Head Relations | ||
| Michael Morrissey, Executive Operations | ||
| PharmD MBA, Executive America | ||
| Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee | ||
| Dashyant Dhanak, Executive Vice President Chief Scientific Officer | ||
| Steven MD, Executive Officer | ||
| Christiana MBA, Executive CFO | ||
| Maria JD, Gen VP | ||
| MBA MBA, Ex America | ||
| Ben Strain, Head Relations | ||
| Sheila Denton, Executive Counsel |
Incyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.008 | ||||
| Return On Asset | -0.0012 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 12.8 B | ||||
| Shares Outstanding | 192.65 M | ||||
| Shares Owned By Insiders | 2.03 % | ||||
| Shares Owned By Institutions | 97.84 % | ||||
| Number Of Shares Shorted | 7 M | ||||
| Price To Earning | 19.17 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.